NASDAQ:BWAY - Brainsway Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $13.75
  • Forecasted Upside: 67.07 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$8.23
▼ -0.07 (-0.84%)
1 month | 3 months | 12 months
Get New Brainsway Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BWAY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BWAY

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$13.75
▲ +67.07% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Brainsway in the last 3 months. The average price target is $13.75, with a high forecast of $15.00 and a low forecast of $12.00. The average price target represents a 67.07% upside from the last price of $8.23.
Buy
The current consensus among 4 contributing investment analysts is to buy stock in Brainsway.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/28/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/26/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/25/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/24/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/22/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/20/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/21/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/20/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/20/2021Northland SecuritiesInitiated CoverageOutperform$15.00High
i
4/1/2021OppenheimerBoost Price TargetOutperform$13.00 ➝ $15.00Medium
i
3/26/2021OppenheimerBoost Price TargetOutperform$13.00 ➝ $15.00High
i
2/17/2021Raymond JamesBoost Price TargetOutperform$9.00 ➝ $12.00Low
i
9/22/2020OppenheimerInitiated CoverageBuy$13.00Medium
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
8/14/2020Cantor FitzgeraldReiterated RatingBuy$13.00Low
i
Rating by K. Mikson at Cantor Fitzgerald
8/13/2020Raymond JamesLower Price TargetOutperform$10.00 ➝ $9.00Medium
i
7/14/2020Cantor FitzgeraldReiterated RatingOverweight$10.00Low
i
Rating by Kyle Mikson CFA at Cantor Fitzgerald
6/24/2020OppenheimerReiterated RatingBuy$13.00Low
i
3/24/2020Raymond JamesLower Price TargetOutperform$13.00 ➝ $9.00High
i
3/24/2020Cantor FitzgeraldLower Price TargetOverweight$17.00 ➝ $13.00High
i
11/26/2019Raymond JamesLower Price TargetOutperform$14.00 ➝ $13.00High
i
5/13/2019CIBCInitiated CoverageOutperform ➝ OutperformHigh
i
5/13/2019Raymond JamesInitiated CoverageOutperform ➝ Outperform$14.00High
i
5/13/2019OppenheimerInitiated CoverageOutperform$17.00High
i
5/13/2019LADENBURG THALM/SH SHInitiated CoverageBuy ➝ Buy$19.00High
i
5/13/2019Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$17.00High
i
Rating by C. Bijou at Cantor Fitzgerald
(Data available from 4/21/2016 forward)
Brainsway logo
Brainsway Ltd., a commercial stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. It offers deep transcranial magnetic stimulation technology for the treatment of major depressive disorders, obsessive-compulsive disorders, bipolar disorders, post traumatic stress disorders, schizophrenia, smoking cessation, Alzheimer's disease, Asperger syndromes, alcohol addictions, attention deficit hyperactivity disorders, Parkinson's disease, and chronic neuropathic pains to transmit electric current flows at varying rates and creating an electromagnetic field that serves to depolarize cortical neurons and activate neural networks in various areas of the brain. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
Read More

Today's Range

Now: $8.23
$8.23
$8.41

50 Day Range

MA: $8.94
$8.30
$9.57

52 Week Range

Now: $8.23
$5.52
$11.04

Volume

300 shs

Average Volume

77,933 shs

Market Capitalization

$130.55 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.39

Frequently Asked Questions

What sell-side analysts currently cover shares of Brainsway?

The following Wall Street analysts have issued reports on Brainsway in the last year: Cantor Fitzgerald, Northland Securities, Oppenheimer Holdings Inc., Raymond James, and Zacks Investment Research.
View the latest analyst ratings for BWAY.

What is the current price target for Brainsway?

4 Wall Street analysts have set twelve-month price targets for Brainsway in the last year. Their average twelve-month price target is $13.75, suggesting a possible upside of 54.1%. Oppenheimer Holdings Inc. has the highest price target set, predicting BWAY will reach $15.00 in the next twelve months. Raymond James has the lowest price target set, forecasting a price of $12.00 for Brainsway in the next year.
View the latest price targets for BWAY.

What is the current consensus analyst rating for Brainsway?

Brainsway currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BWAY will outperform the market and that investors should add to their positions of Brainsway.
View the latest ratings for BWAY.

What other companies compete with Brainsway?

How do I contact Brainsway's investor relations team?

Brainsway's physical mailing address is 19 HARTUM STREET BYNET BUILDING 3RD FL Har HaHotzvim, Jerusalem L3, 9777518. The company's listed phone number is (722) 581-3140 and its investor relations email address is [email protected] The official website for Brainsway is www.brainsway.com.